ESMO 2022: Efficacy and safety of osbutinib in combination with R-CHOP in patients with previously untreated non-GCB DLBCL

Patients with non-GCB DLBCL have a poor prognosis, especially extranodal invasions with strong invasiveness and rapid

From September 9 to 13, the 2022 European Society of Oncology (ESMO) Annual Conference will be held

IHC-confirmed non-GCB DLBCL and PET-CT-confirmed extranodal invasion of patients enrolled in this study

The results of the study showed that 22 patients were enrolled, with a median age of 52 years (21-72), including 10 males, 11 cases with IPI ≥3, 12 cases with double expression (DE) DLBCL, and 19 cases with

The findings suggest that in this single-center clinical practice, the treatment of obutinib in combination with R-CHOP in combination with non-GCB DLBCL with extranodal involvement is more effective and the toxicity is acceptable

Resources:

2022 ESMO: 627MO - Orelabrutinib plus RCHOP for previously untreated non-germinal center b cell-like (GCB) diffuse large b cell lymphoma (DLBCL) patients with extranodal disease